The clinical development of vaccines for HER2+ breast cancer: current landscape and future perspectives

Breast cancer is the most frequent tumor worldwide and 252,710 women will develop the disease in the United States in 2017 [1]. Breast cancer is a heterogeneous disease clinically classified based on presence of hormonal receptors for estrogen and progesterone by immunohistochemistry, and the expression/amplification status of the HER2 protein/oncogene [2,3]. Systemic treatment directed to the HER2 oncoprotein led to unprecedented improvement in clinical outcomes for the subset of patients with breast tumors harboring HER2 overexpression/amplification.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2loL2Yj
via IFTTT